| abstract |
The invention belongs to the field of medicinal chemistry. In particular, the present invention provides novel classes of small molecules that function as dual inhibitors of EGFR and PI3K and have a quinazoline structure, and for treating cancer (eg, cancers associated with mutant KRAS and BRAF). For its use as a medicament (eg, in combination with a MAPK pathway inhibitor (eg, a BRAF inhibitor, a MEK inhibitor, an ERK inhibitor)). |